Better Biosuperiors

Sutro Biopharma Inc. hopes to use a $36.5 million series C round to demonstrate the potential of its protein modification technology and the company's ability to manufacture the molecules, which can incorporate non-natural amino acids.

The company is focused on chemical modifications of protein therapeutics to enable the creation of both biosuperiors and novel therapeutics...